Cibinqo® (abrocitinib) – Expanded indication
February 10, 2023 - Pfizer announced the FDA approval of Cibinqo (abrocitinib), for the treatment of adults and pediatric patients 12 years of age and older with refractory, moderate-to-severe atopic dermatitis whose disease is not adequately controlled with other systemic drug products, including biologics, or when use of those therapies is inadvisable.
Top